CFMEV-107 is under clinical development by Cell Factory and currently in Phase I for Crohn’s Disease (Regional Enteritis). According to GlobalData, Phase I drugs for Crohn’s Disease (Regional Enteritis) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CFMEV-107’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CFMEV-107 overview
CFMEV-107 is under development for the treatment of crohn’s disease (drug resistant perianal fistulae). The drug candidate comprises of mesenchymal stem cell (MSC) derived extracellular vesicles (exosomes). Extracellular vesicles (EVs) are nanometer-size particles comprising proteins, growth factors, mRNA and other molecules encapsulated in a lipid sphere.
Cell Factory overview
The Cell-Factory BVBA (The Cell-Factory), is a biotech company that develops new therapies in the field of regenerative medicine. The company offers development, clinical translation and commercialization of the advanced extracellular vesicles biologic drugs and autologous stem cell therapies. Its regenerative medicines comprise extracellular vesicles, exosomes and autologous stem cells for the treatment of crohn’s disease, drug-resistant epilepsy and cerebral palsy. The Cell-Factory also provides technological development for regenerative medicines and diagnostics. It products in therapeutic areas of neurology, orthopedics, gastroenterology, ulcers, wound healing and cardiovascular diseases. The Cell-Factory is headquartered in Antwerp, Belgium.
For a complete picture of CFMEV-107’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
